Vistagen Therapeutics Files 8-K
Ticker: VTGN · Form: 8-K · Filed: Apr 1, 2024 · CIK: 1411685
| Field | Detail |
|---|---|
| Company | Vistagen Therapeutics, Inc. (VTGN) |
| Form Type | 8-K |
| Filed Date | Apr 1, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-update, filing
Related Tickers: VTGN
TL;DR
VTGN filed an 8-K on 4/1. Basic corporate info updated.
AI Summary
Vistagen Therapeutics, Inc. filed an 8-K on April 1, 2024, reporting other events and financial statements. The filing details the company's principal executive offices located at 343 Allerton Avenue, South San Francisco, California, 94080, and its telephone number (650) 577-3600. The company was incorporated in Nevada and its fiscal year ends on March 31.
Why It Matters
This 8-K filing provides updated corporate information and signals ongoing regulatory compliance for Vistagen Therapeutics.
Risk Assessment
Risk Level: low — This filing is a routine corporate update and does not contain significant financial or operational news that would inherently increase risk.
Key Players & Entities
- Vistagen Therapeutics, Inc. (company) — Registrant
- 343 Allerton Avenue, South San Francisco, California, 94080 (location) — Principal executive offices
- April 1, 2024 (date) — Date of earliest event reported
- Nevada (location) — State of incorporation
FAQ
What is the primary purpose of this 8-K filing for Vistagen Therapeutics?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of April 1, 2024.
Where are Vistagen Therapeutics' principal executive offices located?
Vistagen Therapeutics' principal executive offices are located at 343 Allerton Ave., South San Francisco, California, 94080.
What is Vistagen Therapeutics' telephone number?
Vistagen Therapeutics' telephone number is (650) 577-3600.
In which state was Vistagen Therapeutics incorporated?
Vistagen Therapeutics was incorporated in Nevada.
When does Vistagen Therapeutics' fiscal year end?
Vistagen Therapeutics' fiscal year ends on March 31.
Filing Stats: 456 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2024-04-01 17:25:13
Key Financial Figures
- $0.001 — ch registered Common Stock , par value $0.001 per share VTGN Nasdaq Capital Market
Filing Documents
- vtgn20240401_8k.htm (8-K) — 21KB
- ex_648753.htm (EX-99.1) — 14KB
- 0001437749-24-010427.txt ( ) — 169KB
- vtgn-20240401.xsd (EX-101.SCH) — 3KB
- vtgn-20240401_def.xml (EX-101.DEF) — 11KB
- vtgn-20240401_lab.xml (EX-101.LAB) — 15KB
- vtgn-20240401_pre.xml (EX-101.PRE) — 11KB
- vtgn20240401_8k_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events On April 1, 2024, Vistagen Therapeutics, Inc. (the " Company ") issued a press release to announce that it has enrolled the first patient in its PALISADE-3 Phase 3 trial of fasedienol, an investigational pherine candidate in development for the acute treatment of social anxiety disorder. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits . (d) Exhibits Index Exhibit No. Description 99.1 Press Release issued by Vistagen Therapeutics, Inc., dated April 1, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
Signatures
Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Vistagen Therapeutics, Inc. Date: April 1, 2024 By: /s/ Shawn K. Singh Shawn K. Singh Chief Executive Officer